Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 12:00 PM CET
Settings

Settings

Goto Application

1. WO2022006548 - INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF

Publication Number WO/2022/006548
Publication Date 06.01.2022
International Application No. PCT/US2021/040361
International Filing Date 02.07.2021
IPC
A61K 38/17 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
A61K 38/20 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
20Interleukins
C07K 1/107 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
1General processes for the preparation of peptides
107by chemical modification of precursor peptides
Applicants
  • BRIDGENE BIOSCIENCES, INC. [US]/[US]
Inventors
  • ZHANG, Chao
  • BISHOP, Michael, J.
  • CHEN, Hang
  • CAO, Ping
Agents
  • HAILE, Lisa, A.
  • HIERHOLZER, Matthew, J.
  • HWANG, Pamela, E.
  • JACKSON, Blake
  • LIMBACH, Alan, A.
Priority Data
63/047,73602.07.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF
(FR) INHIBITEURS D'ONCOPROTÉINES YAP/TAZ-TEAD, LEUR SYNTHÈSE ET LEUR UTILISATION
Abstract
(EN) Disclosed herein are synthesis and use of covalent inhibitors selective for Transcriptional Enhancer Factor TEF-1 (TEAD1), which can be used for treatment of cancers such as glioblastoma, gastric cancer, colorectal cancer, pancreatic ductal adenocarcinoma (PDAC), and malignant pleural mesothelioma (MPM). Further disclosed herein are pharmaceutical compositions including the TEAD1 inhibitor and methods of treating cancers using the same.
(FR) Sont divulguées ici la synthèse et l'utilisation d'inhibiteurs covalents sélectifs pour le facteur d'activation transcriptionnel TEF-1 (TEAD1) qui peuvent être utilisés pour le traitement de cancers tels que le glioblastome, le cancer gastrique, le cancer colorectal, l'adénocarcinome canalaire du pancréas (PDAC) et le mésothéliome pleural malin (MPM). Sont en outre divulguées ici des compositions pharmaceutiques comprenant l'inhibiteur TEAD1 et des méthodes de traitement de cancers faisant intervenir lesdites compositions.
Latest bibliographic data on file with the International Bureau